Skip to main content
. 2023 Nov 17;11(11):3084. doi: 10.3390/biomedicines11113084

Figure 2.

Figure 2

Levels of plasma ETP decreased with a combination therapy of RASi and SGLT2is compared to RASi monotherapy. Longitudinal plasma endotrophin (ETP) levels stratified by treatment group over time (p for slope difference = 0.002). RASi: renin–angiotensin system inhibitor; SGLT2i: sodium–glucose co-transporter 2 inhibitor.